• Aucun résultat trouvé

pediatric acute myeloid leukemia

H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations

H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations

... Table 2. EZH2 inhibitors and their status in clinical development. Modified from [23]. 1.1.8 Inhibition of PRC2 Activity through H3K27 Mutation Recently, lysine-to-methionine (KM) mutations affecting H3K27 have been ...

89

Dexamethasone in hyperleukocytic acute myeloid leukemia

Dexamethasone in hyperleukocytic acute myeloid leukemia

... chemogenomic approach, Simon et al. demonstrated that AML samples bearing inactivating RUNX1 mutations are particularly sensitive to glucocorticoids. 21 Our study is the first to detect a significant clinical correlation ...

12

Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the LEA program

Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the LEA program

... Many pediatric late anthracycline cardiotoxicity studies have concerned heterogeneous diagnostic ...in acute lym- phoblastic leukemia, whereas the highest doses of anthra- cycline are given in ...

5

Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia

Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia

... Mechanistically, several transcriptional factors, such as SREBP1/2, LXR, ChREBP, or CEBPα/β regulate de novo lipogenesis and lipid metabolism in various cell types. Interestingly, Ricoult et al. [65] have shown that, in ...

19

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia

... Abstract: Acute myeloid leukaemia (AML) is a clonal disorder that affects hematopoietic stem cells or myeloid progenitors. One of the most common mutations that results in AML occurs in the gene ...

24

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

... three dose intensity levels by using the threshold myeloa- blative dose as the intermediate dose level and assigning all doses below or above to the low or high dose level, respectively. For each of these components, we ...

12

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.

... using established criteria. 18 Chronic GVHD was classified as limited or extensive according to usual criteria. 19 GRFS after HSCT was defined as survival in the absence of grade 3 –4 acute GVHD, extensive chronic ...

8

Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

... Another prospective study of prophylactic DLI in patients with high-risk acute leukemia has been reported by Liga et al. 19 2 years ago. In that study, patients were given allo-HCT following a low-dose (10 ...

3

The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs

The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs

... http://dx.doi.org/10.1016/j.celrep.2014.05.016 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ). SUMMARY Chemotherapeutic drugs used in the treatment of ...

10

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)

... leukemia progression, we used two different patient-derived xenograft (PDX) models: Patient 17 CXCR4-low and P15 CXCR4-high models, characterized by relatively low and high CXCR4 expression, respectively. Weekly ...

14

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.

... INTRODUCTION Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous disease characterized by accumulation of a variety of somatically acquired genetic aberrations in ...

10

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia

... Nras mutant AMLs from this screen: Nras G12D + Evi1 contains a clonal Evi1 integration and expresses high transcript levels while the control Nras G12D AML does not. Immunoblot analysis revealed markedly elevated levels ...

34

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia

... Relevant preclinical mouse models are crucial to screen new therapeutic agents for acute myeloid leukemia (AML). Current in vivo models based on the use of patient samples are not easy to establish ...

8

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission

... Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission Q 5 Erica D. Warlick 1 , * , Kristjan Paulson ...

7

Practical management of Chronic Myeloid Leukemia in Belgium

Practical management of Chronic Myeloid Leukemia in Belgium

... chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor ...Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk ...

17

Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia

Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia

... FIGURE 3 | Genome-wide genes/cell signaling pathways associated with CLIC4 expression. (A) Volcano plot of the genome-wide gene profiles between the CLIC4 high and CLIC4 low groups. (B) Gene expression heatmap. The top ...

14

Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB

Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB

... 2.1 Introduction The eukaryotic translation initiation factor 4E (EIF4E) is a potent oncogene which is inappropriately elevated in about 30% of human cancers including the M4 and M5 subtypes of Acute Myelogenous ...

154

Acute lymphoblastic leukemia in children

Acute lymphoblastic leukemia in children

... Le nombre (n = 13 soit 16,5 %) d’échecs thé- rapeutiques (rechutes et patients réfractaires : plus de 25 % de blastes après l’induction) que nous avons observé est bas mais le taux de “r[r] ...

7

Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials

Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials

... Secondary acute myeloid leukemia (sAML) describes patients (pts) with a history of malignant or non-malignant disease or AML secondary to environmental, occupational or therapeutic ...

3

Caractérisation de l'oncogène MLF1 (Myeloid Leukemia Factor 1)

Caractérisation de l'oncogène MLF1 (Myeloid Leukemia Factor 1)

... L’interaction de ces différentes protéines avec les 14-3-3 résulte en leur implication dans différents processus métaboliques importants pour la cellule tels que: la régulation du cycle [r] ...

116

Show all 1078 documents...

Sujets connexes